Telix Pharmaceuticals Schedules FY2025 Results Amid Key Regulatory Milestones
Event summary
- Telix Pharmaceuticals will release its full-year results for FY2025 on February 20, 2026 AEDT.
- An investor webcast and conference call are scheduled for the same day at 9:30 a.m. AEDT (February 19, 2026 EST).
- The company is preparing NDA resubmission for TLX101-Px and BLA resubmission for TLX250-Px.
- Telix operates globally with headquarters in Melbourne and offices in the U.S., UK, Brazil, Canada, Europe, and Japan.
The big picture
Telix Pharmaceuticals is navigating a critical phase in its growth trajectory, with regulatory submissions for key radiopharmaceutical candidates pending. The company's global footprint positions it to capitalize on unmet medical needs in oncology and rare diseases, but execution risks remain high as it balances commercialization efforts with clinical development.
What we're watching
- Regulatory Milestones
- The pace at which Telix secures NDA and BLA approvals for TLX101-Px and TLX250-Px will determine its commercialization timeline.
- Financial Performance
- Whether FY2025 results reflect sustained revenue growth amid increasing R&D investments in radiopharmaceuticals.
- Global Expansion
- How Telix's international operations impact its ability to scale production and distribution of therapeutic products.
Our editorial coverage:
Related topics